Are ctDNA monitoring tests being used in clinical practice? Which ctDNA monitoring tests are oncologists currently using, and why? What are their unmet needs and expectations from a new test? Purdie Pascoe is delighted to announce the findings from the first wave of our syndicated ctDNA Cancer Monitoring study have been published.

PMCF is an essential aspect of medical device regulation. In this interview Marcus Torr provides a breakdown of the best approach, including how it can improve patient safety as well as the challenges it poses for small to medium-sized enterprises.

BCorp is rapidly becoming the industry designation that a business is meeting high standards of performance, accountability, and transparency on factors from employee benefits and charitable giving to supply chain practices and input materials. It goes beyond sustainability to recognise how companies interact with the environment, their community, their customers and their employees.

We’re thrilled to announce that Purdie Pascoe has expanded our footprint with the opening of a US office! Meet our team of seasoned market researchers with over 30 years of global healthcare experience and deep MedTech specialization.

In the ever-evolving landscape of brand strategy, Byron Sharp's theories of brand salience and availability have become guiding lights for marketers. Understanding the crucial interplay between these elements is key to crafting a brand that stands out and remains top-of-mind. At Purdie Pascoe, we have built our own Brand Equity Model, based on Byron Sharp’s marketing science.

PMCF Surveys – How to Ensure Success? In this webcast you will learn a range of best practice tips and tricks to ensure you are compliant. Co-hosted by Purdie Pascoe PMCF experts and Qserve.

Artificial Intelligence (AI), particularly Generative AI, marks a substantial breakthrough in market research. In the ever-evolving landscape of applications and tools, staying current is half the battle. At Purdie Pascoe, we prioritize staying updated and adapting to market shifts while also being prudent in deploying AI, upholding data and privacy compliance.

Post-market clinical follow-up (PMCF) surveys have become a significant topic in the industry, offering a cost-effective solution for PMCF data collection. However, their effective implementation can be challenging. In this article, the PMCF experts at Purdie Pascoe focus on high-quality, case/patient-specific PMCF surveys that provide Level 4 data.

I still remember my first exposure to market research: it was in the late 90s, a few years before I moved into the industry myself, and I was working for a cellphone company. We were exploring the potential for mobile internet services, from shopping and gaming to stock trading and betting.

Watch this webcast with experts from Purdie Pascoe and Global RWC. Watch the webcast to gain key learnings such as proper survey planning , best practices for PMCF survey design  and what to do with your PMCF data.

Tumor agnostic indications present specific challenges that must be addressed to achieve a successful launch and ensure wide access for all patients. To prepare for these complex product and indications launches, it is paramount for commercial teams to gain insights on tumor agnostic testing behaviors, including awareness, adoption, drivers and barriers.

So, we now have our key brand metrics and understand which channels are preferred by our customers. But how do we turn this information into an action plan?

In brand equity research, stated importance is often used as the key measure of importance. Survey questions ask respondents to rank or rate attributes, providing researchers with direct, explicit data. While this approach provides a simple and cost-effective measure of importance, it suffers from inherent limitations.

In the healthcare industry, the COVID pandemic changed how we interact with our customers. We saw a rapid adoption of TeleHealth. Unable to access hospitals and clinics, sales reps had to find new ways of engaging with healthcare professionals, and healthcare companies increased their presence on social media platforms. We even had to learn how to make an impact at virtual conferences.

This article is the second part in a series where we examine the best way to drive brand growth and the market research approaches needed to support it.

This short article is the first part in a series where we examine the best way to drive brand growth and the market research approaches needed to support it.

Have you ever wondered what the best way is to drive the growth of your brand? At Purdie Pascoe, we have been looking into this, from a market research viewpoint, starting with a determination to be led by science rather than unfounded theories.

Many of the projects we do at Purdie Pascoe involve pricing or even have pricing as the principal objective. Our clients are constantly coming up with great new products, or improvements to existing ones, and they want to know if people will pay for them.

4th Medical Devices Regulatory and Compliance Online Summit (Vonlanthen Group)

Post market clinical follow-up (PMCF) surveys:

‘The ever-changing landscape’

Date: 24 - 25 March, 2022

Location: Virtual / Zoom

Doctors hate marketing. They’re always telling us that. They’re only interested in cold, hard evidence, not catchy slogans, or pictures of hopeful looking patients. Give us the facts, they say, don’t shower us in sentiment. Or (surely one of the most frustrating things for a marketeer to hear) “just make it less marketing-y”. But… we all know that underneath those white coats they’re just human beings like you and me.

One of the key aims for market researchers is to help our clients truly understand how their customers make decisions, and to identify and ideally quantify the most important choice drivers. Conjoint is one of our key tools for doing this.

Decentralized clinical trials have become the new normal during Covid times, and many advocate for this novel approach to grow into the industry standard. The days of solely focusing on key large centres for patient accrual are over, and this shift in paradigm can only benefit a greater number of cancer patients, everywhere.